ArticleNuclear medicine communications2026
Grading and detecting gastroenteropancreatic neuroendocrine neoplasms with dual-tracer ( 18 F-AlF-NOTA-octreotide/ 18 F-FDG) PET/CT: a metabolic parameter-based study.
Article in Nuclear medicine communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo evaluate quantitative metabolic indices from dual-tracer 18 F-AlF-NOTA-octreotide ( 18 F-AlF-OC) and 18 F-fluorodeoxyglucose (FDG) PET/computed tomography (CT) for grading gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs), focusing on total lesion glycolysis ratio (TLGR).
methodsThis retrospective study included 34 patients with GEP-NENs (198 target lesions) who underwent both 18 F-AlF-OC and 18 F-FDG PET/CT. Parameters included maximum standardized uptake value (SUV max ), total lesion glycolysis (TLG), SUV ratio (SUVR), and TLGR (ratio of 18 F-AlF-OC volumetric somatostatin receptor uptake to 18 F-FDG TLG by conventional TLG framework). Diagnostic performance for differentiating G1/G2 from G3/neuroendocrine carcinoma (NEC) and neuroendocrine tumor (NET) from NEC was assessed using receiver operating characteristic (ROC) analysis. Incremental value was evaluated using Δarea under the curve (AUC) and continuous net reclassification improvement with patient-level cluster bootstrap resampling. Generalized estimating equation (GEE) models accounted for multiple lesions per patient. Internal validation used leave-one-patient-out cross-validation.
results18 F-AlF-OC detected more lesions in G1/G2 NETs, while detection was similar in NEC. In ROC analysis, TLGR, SUVR, and TLGR + SUVR yielded AUCs of 0.760, 0.760, and 0.767 for G1/G2 versus G3/NEC, and 0.811, 0.829, and 0.827 for NET versus NEC, respectively. Adding TLGR to SUVR or FDG SUV max provided only modest improvement. TLGR was significant alone in GEE models but attenuated after SUVR adjustment, and cross-validation showed reduced out-of-sample performance.
conclusionDual-tracer PET/CT provides complementary information for GEP-NEN grading. TLGR is an exploratory volumetric dual-tracer parameter, but its incremental value beyond SUVR and FDG SUV max is limited. Further validation is required.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.